- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease
- Interventions
- AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo
- Biological · Other
- Lead sponsor
- Institute for Molecular Medicine
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Boca Raton, Florida • Miami Lakes, Florida • Stuart, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 42
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Aging
- Interventions
- repetitive transcranial magnetic stimulation (rTMS)
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Depression, Drive
- Interventions
- F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 150 participants
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Interventions
- DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
- Biological
- Lead sponsor
- Nuravax, Inc.
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Miami Lakes, Florida
- Conditions
- Preclinical Alzheimer's Disease
- Interventions
- Obicetrapib 10 mg, Matching placebo tablets
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Interventions
- AADvac1, Donanemab
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Preclinical Alzheimer's Disease
- Interventions
- Gemfibrozil, Placebo
- Drug
- Lead sponsor
- Gregory Jicha, 323-5550
- Other
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Interventions
- Active rTMS, Sham rTMS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 20 Years to 100 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer's Disease
- Interventions
- Trontinemab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 1,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Irvine, California • Santa Ana, California • Maitland, Florida + 1 more
- Conditions
- Alzheimers Disease
- Interventions
- CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
- Biological · Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 78
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
- Conditions
- Alzheimer Disease, Dementia, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
- Interventions
- Financial Incentives, Message
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 44,844 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Martinez, California
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
- Interventions
- Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
- Other · Diagnostic Test · Genetic
- Lead sponsor
- University of Rhode Island
- Other
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
- Conditions
- APOE 4
- Interventions
- AGB101 220 mg, Placebo
- Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment
- Interventions
- EEG scan
- Device
- Lead sponsor
- Metabolic Therapy Inc.
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Alzheimer Disease
- Interventions
- JNJ-64042056, Placebo
- Drug
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Industry
- Eligibility
- 55 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Irvine, California • Murrieta, California + 31 more
- Conditions
- Alzheimer's Disease
- Interventions
- icosapent ethyl (IPE), gel cap placebo
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Novoic Limited
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Santa Ana, California
- Conditions
- Alzheimer's Disease
- Interventions
- Aerobic Exercise, Standard of Care
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Interventions
- AADvac1, Tau2
- Drug
- Lead sponsor
- Paul S. Aisen
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
- Conditions
- Aging
- Interventions
- Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions, Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Alzheimers Disease
- Interventions
- CNP520 50mg, CNP520 15mg, Matching placebo
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 1,145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 95
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
- Interventions
- Not listed
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 39 more
- Conditions
- Preclinical Alzheimer's Disease
- Interventions
- Exergame
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 65 Years to 99 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota